A dose-volume histogram analysis of the seminal vesicles in men treated with conformal radiotherapy to 'prostate alone'.
OBJECTIVE
There is no consensus on whether the seminal vesicles should be included in the clinical target volume (CTV) for radiotherapy of localized prostate cancer. To inform the debate, we have undertaken a dose-volume histogram (DVH) analysis of the seminal vesicles in patients treated with escalated dose conformal radiation to 'prostate alone'.


METHODS
Twenty-five consecutive patients receiving conformal radiation to the prostate, to a dose of 75.6 Gy in 42 daily fractions, were studied. The CTV was defined as the prostate only, and the planning target volume (PTV) was defined by a 10 mm margin, except posteriorly where the margin was 7 mm. DVHs were calculated for the entire seminal vesicles, and for 6 mm segments through the seminal vesicles.


RESULTS
Incorporating a correction for organ motion, the D90 (minimum dose received by 90% of the volume of interest) for the most inferior 6 mm volume of the seminal vesicles (SV1) ranged from 25 to 70 Gy, and the percentage volume of SV1 receiving 50 Gy ranged from 47-100%. Using a D90 of 50 Gy as a cut-off, eight of the 25 patients had unacceptably low-dose coverage of SV1.


CONCLUSIONS
Escalated dose conformal radiation to the 'prostate alone' does not ensure adequate dose coverage of even the most inferior 6 mm of the seminal vesicles. We consider such treatment acceptable in patients at low risk of seminal vesicle involvement (T1/2ab, Gleason < or = 7, PSA < 10 ng/ml). In higher risk patients, if it is deemed necessary to treat the possibility of sub-clinical seminal vesicle involvement, this should be reflected in the definition of the CTV.
Department of Radiation Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada.
Christopher
C
Parker
Tara
T
Haycocks
Andrew
A
Bayley
Hamideh
H
Alasti
Padraig
P
Warde
Charles
C
Catton
D004307:Dose-Response Relationship, Radiation; D006801:Humans; D008297:Male; D015999:Multivariate Analysis; D011471:Prostatic Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D011879:Radiotherapy Dosage; D020266:Radiotherapy, Conformal; D012669:Seminal Vesicles / Q000473:pathology*